5 Oversold Growth Stocks to Buy Right Now

3. Zoetis Inc. (NYSE:ZTS)

14-day RSI as of April 5: 21.07

Latest Trailing P/E Ratio: 29.54

Number of Hedge Fund Holders: 50

Parsippany, New Jersey-based Zoetis Inc. (NYSE:ZTS) is a leading animal health company with a portfolio and pipeline of medicines, vaccines, diagnostics, and technologies offered in over 100 countries. Formerly a subsidiary of Pfizer Inc. (NYSE:PFE), the company became independent through a spinoff in 2013.

Zoetis Inc. (NYSE:ZTS) has been continuously making efforts to increase its product franchises in major markets. During the fourth quarter, the company received approvals for Simparica Trio, the company’s triple combination oral parasiticide for dogs, in China. While the company’s injectable monoclonal antibody for the alleviation of pain associated with osteoarthritis in cats, Solensia, received approval in Brazil.

Zoetis Inc. (NYSE:ZTS) has paid regular dividends since its spinoff from Pfizer Inc. (NYSE:PFE) with consecutive dividend increases for several years. The board of directors of the company declared a dividend of $0.432 per share for Q2 2024, on February 6.

As of Q4 2023, Zoetis Inc. (NYSE:ZTS) shares were owned by 50 hedge funds, one of the highest on our list of 11 oversold growth stocks to buy right now. William Von Mueffling’s Cantillon Capital Management was its lead hedge fund shareholder with ownership of 1.4 million shares valued at $280 million.